SG11201602175VA - Laquinimod combination therapy for treatment of multiple sclerosis - Google Patents
Laquinimod combination therapy for treatment of multiple sclerosisInfo
- Publication number
- SG11201602175VA SG11201602175VA SG11201602175VA SG11201602175VA SG11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA SG 11201602175V A SG11201602175V A SG 11201602175VA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- multiple sclerosis
- combination therapy
- laquinimod
- laquinimod combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883698P | 2013-09-27 | 2013-09-27 | |
| PCT/US2014/057705 WO2015065628A2 (en) | 2013-09-27 | 2014-09-26 | Laquinimod combination therapy for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201602175VA true SG11201602175VA (en) | 2016-04-28 |
Family
ID=52740749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602175VA SG11201602175VA (en) | 2013-09-27 | 2014-09-26 | Laquinimod combination therapy for treatment of multiple sclerosis |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20150094332A1 (enExample) |
| EP (1) | EP3049075A4 (enExample) |
| JP (1) | JP2016533323A (enExample) |
| KR (1) | KR20160085757A (enExample) |
| CN (1) | CN105848653A (enExample) |
| AR (1) | AR097792A1 (enExample) |
| AU (1) | AU2014342917A1 (enExample) |
| BR (1) | BR112016006582A2 (enExample) |
| CA (1) | CA2925493A1 (enExample) |
| EA (1) | EA201690673A1 (enExample) |
| IL (1) | IL244620A0 (enExample) |
| MX (1) | MX2016003763A (enExample) |
| SG (1) | SG11201602175VA (enExample) |
| TW (1) | TW201601722A (enExample) |
| UY (1) | UY35748A (enExample) |
| WO (1) | WO2015065628A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| BRPI0713694A2 (pt) * | 2006-06-12 | 2012-10-30 | Teva Pharma | composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica |
| CN107308162A (zh) * | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
| EP2736335A4 (en) * | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
-
2014
- 2014-09-26 EP EP14857795.0A patent/EP3049075A4/en not_active Withdrawn
- 2014-09-26 TW TW103133660A patent/TW201601722A/zh unknown
- 2014-09-26 BR BR112016006582A patent/BR112016006582A2/pt not_active IP Right Cessation
- 2014-09-26 US US14/498,024 patent/US20150094332A1/en not_active Abandoned
- 2014-09-26 AR ARP140103582A patent/AR097792A1/es unknown
- 2014-09-26 KR KR1020167011039A patent/KR20160085757A/ko not_active Withdrawn
- 2014-09-26 AU AU2014342917A patent/AU2014342917A1/en not_active Abandoned
- 2014-09-26 UY UY0001035748A patent/UY35748A/es not_active Application Discontinuation
- 2014-09-26 CN CN201480053575.8A patent/CN105848653A/zh active Pending
- 2014-09-26 MX MX2016003763A patent/MX2016003763A/es unknown
- 2014-09-26 EA EA201690673A patent/EA201690673A1/ru unknown
- 2014-09-26 JP JP2016516547A patent/JP2016533323A/ja not_active Withdrawn
- 2014-09-26 SG SG11201602175VA patent/SG11201602175VA/en unknown
- 2014-09-26 CA CA2925493A patent/CA2925493A1/en active Pending
- 2014-09-26 WO PCT/US2014/057705 patent/WO2015065628A2/en not_active Ceased
-
2016
- 2016-03-15 IL IL244620A patent/IL244620A0/en unknown
- 2016-05-31 US US15/169,139 patent/US20160271094A1/en not_active Abandoned
-
2017
- 2017-07-06 US US15/643,214 patent/US20170304253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160085757A (ko) | 2016-07-18 |
| CA2925493A1 (en) | 2015-05-07 |
| MX2016003763A (es) | 2016-10-28 |
| AR097792A1 (es) | 2016-04-13 |
| UY35748A (es) | 2015-04-30 |
| US20150094332A1 (en) | 2015-04-02 |
| IL244620A0 (en) | 2016-04-21 |
| US20170304253A1 (en) | 2017-10-26 |
| EP3049075A4 (en) | 2017-05-03 |
| WO2015065628A2 (en) | 2015-05-07 |
| AU2014342917A1 (en) | 2016-04-21 |
| US20160271094A1 (en) | 2016-09-22 |
| EP3049075A2 (en) | 2016-08-03 |
| EA201690673A1 (ru) | 2016-08-31 |
| WO2015065628A3 (en) | 2015-10-29 |
| CN105848653A (zh) | 2016-08-10 |
| BR112016006582A2 (pt) | 2017-08-01 |
| TW201601722A (zh) | 2016-01-16 |
| JP2016533323A (ja) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL243976B (en) | kdm1a inhibitors for disease treatment | |
| PT2879672T (pt) | Terapia combinada para o tratamento da esclerose múltipla | |
| PT3033086T (pt) | Terapia de combinação para o tratamento de cancro | |
| IL241101A0 (en) | Medicinal uses of empagliflozin | |
| IL244014A0 (en) | Combined therapy for the treatment of glioblastoma | |
| IL241102A0 (en) | Medicinal uses of empagliflozin | |
| ZA201408820B (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| PL2981271T3 (pl) | Zastosowania terapeutyczne empagliflozyny | |
| IL240014A0 (en) | Treatment of multiple sclerosis using laquinimod | |
| IL245373A0 (en) | Treatment of glaucoma by laquinimod | |
| ZA201506396B (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
| EP3104869A4 (en) | Treatment of pain | |
| IL244620A0 (en) | A drug combination including laquinimod for the treatment of multiple sclerosis | |
| IL243487A0 (en) | Treatment of multiple sclerosis through induction by alemtuzumab and administration of quinimod | |
| HK1225291A1 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| GB2525530B (en) | Treatment of hard surfaces | |
| GB201317564D0 (en) | Therapeutic for the treatment of Lung Cancer |